Barclays lowered the firm’s price target on Cellectis (CLLS) to $5 from $7 and keeps an Overweight rating on the shares following the Q3 report.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLLS: